Conduit Pharmaceuticals Inc. has announced a strategic partnership with Manoira to advance the development of AZD1656 and AZD5658 in the animal health sector. This collaboration aims to leverage cutting-edge reformulation expertise to accelerate human clinical programs while exploring commercial potential in the $15 billion animal health market. By entering this joint development agreement, Conduit seeks to generate cross-species insights and fast-track its therapeutic pipeline, all while maintaining full ownership of intellectual property and data. This partnership not only enhances Conduit's core human therapeutic offerings but also opens new revenue opportunities in the growing veterinary market, aligning with its strategy of innovative, high-return collaborations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.